In:
Tumori Journal, SAGE Publications, Vol. 76, No. 1 ( 1990-02), p. 35-37
Abstract:
Thirty-two patients with advanced non-small cell lung cancer (NSCLC) were entered in this study to evaluate the efficacy and toxicity of a chemotherapy schedule including cisplatin (C) 40 mg/m 2 intravenously (i.v.) on days 1–3; vindesine (V) 3 mg/m 2 i.v. on day 1, and cytarabine (ara-C) 15 mg/m 2 subcutaneously every 12 hours on days 1–3 (total dose: 90 mg/m 2 ). Cisplatin was administered simultaneously with one dose of ara-C. Cycles were repeated every 28 days. Five patients out of 28 (18 %) fully evaluable for response presented partial remissions. No complete response was observed. Median survival was 8 months and median duration of response was 4 months. Hematologic toxicity was severe in 3 patients. There were no toxicity-related deaths. Other adverse reactions included nausea and vomiting, alopecia and peripheral neuropathy. We conclude that this chemotherapy combination is marginally effective against NSCLC showing in this group of patients a low number of responses of short duration without a significant impact on survival.
Type of Medium:
Online Resource
ISSN:
0300-8916
,
2038-2529
DOI:
10.1177/030089169007600109
Language:
English
Publisher:
SAGE Publications
Publication Date:
1990
detail.hit.zdb_id:
280962-X
detail.hit.zdb_id:
2267832-3
Permalink